{"id":51386,"date":"2022-11-30T13:02:13","date_gmt":"2022-11-30T12:02:13","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/corner-therapeutics-to-present-pre-clinical-data-on-their-novel-dendritic-cell-hyperactivation-platform-at-the-4th-inflammasome-therapeutics-summit\/"},"modified":"2022-11-30T13:02:13","modified_gmt":"2022-11-30T12:02:13","slug":"corner-therapeutics-to-present-pre-clinical-data-on-their-novel-dendritic-cell-hyperactivation-platform-at-the-4th-inflammasome-therapeutics-summit","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/corner-therapeutics-to-present-pre-clinical-data-on-their-novel-dendritic-cell-hyperactivation-platform-at-the-4th-inflammasome-therapeutics-summit\/","title":{"rendered":"Corner Therapeutics to Present Pre-Clinical Data on their Novel Dendritic Cell Hyperactivation Platform at the 4th Inflammasome Therapeutics Summit"},"content":{"rendered":"
\n

WATERTOWN, Mass.–(BUSINESS WIRE)–Corner Therapeutics<\/a>, a biotechnology company exploiting a new scientific paradigm to boost the intelligence of the natural immune response to disease, today announced three presentations of data on its dendritic cell hyperactivation (hDC) platform at the 4th Inflammasome Therapeutics Summit, taking place November 29 to December 1, 2022 in Boston, Massachusetts.\n<\/p>\n

<\/a><\/p>\n

\nCorner has developed proprietary chemical mimics called DC hyperactivators, which stimulate durable protective immunity through the production of polyclonal populations of long-lived memory T cells. DC hyperactivators operate by stimulating inflammasome activities within living dendritic cells, which function to orchestrate T cell immunity. Corner\u2019s technology is particularly effective at inducing protective immunity in elderly or immunocompromised populations, where immune system dysfunction raises the risk of infection and cancer.\n<\/p>\n

\nPreclinical data in human and mouse model systems demonstrate the ability of Corner Therapeutics\u2019 DC hyperactivators to stimulate inflammasomes in dendritic cells that have migrated to lymph nodes, where the activation of tumor- or infection-specific T cells occurs.\n<\/p>\n\n\n\n\n\n\n\n
\n

\nPresentation Overview<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nTitle:<\/b>\n<\/p>\n<\/td>\n

\n

\nA Unique Dendritic Cell Activation State Utilizes Inflammasomes to Stimulate Anti-tumor Immunity in Mice\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nPresenter:<\/b>\n<\/p>\n<\/td>\n

\n

\nKelsey Finn, PhD\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nDates\/Times:<\/b>\n<\/p>\n<\/td>\n

\n

\nWednesday, November 30, 1:00 pm – 2:00 pm\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\nThursday, December 1, 10:30 am – 11:30 am\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nLocation:<\/b>\n<\/p>\n<\/td>\n

\n

\nHilton Boston Logan Airport, Boston, MA\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n\n\n\n\n\n\n\n
\n

\nPresentation Overview<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nTitle:<\/b>\n<\/p>\n<\/td>\n

\n

\nA Unique Dendritic Cell Activation State Utilizes Inflammasomes to Stimulate Memory T Cell Responses in Humans\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nPresenter:<\/b>\n<\/p>\n<\/td>\n

\n

\nEmily Gosselin, PhD\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nDates\/Times:<\/b>\n<\/p>\n<\/td>\n

\n

\nWednesday, November 30, 1:00 pm – 2:00 pm\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\nThursday, December 1, 10:30 am – 11:30 am\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nLocation:<\/b>\n<\/p>\n<\/td>\n

\n

\nHilton Boston Logan Airport, Boston, MA\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nCorner\u2019s scientific cofounder and Advisor, Jonathan Kagan, PhD, will present a seminar on the control of anti-tumor immunity in elderly populations, exploring potential cancer biomarkers and their relation to inflammasome activity, and how this knowledge can be translated into therapeutic regimens for patients.\n<\/p>\n\n\n\n\n\n\n
\n

\nPresentation Overview<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nTitle:<\/b>\n<\/p>\n<\/td>\n

\n

\nInflammasomes and the Control of Anti-Tumor Immunity\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nPresenter:<\/b>\n<\/p>\n<\/td>\n

\n

\nJonathan Kagan, PhD\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nDate\/Time:<\/b>\n<\/p>\n<\/td>\n

\n

\nThursday, December 1, 2022, 3:30 pm\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nLocation:<\/b>\n<\/p>\n<\/td>\n

\n

\nHilton Boston Logan Airport, Boston, MA\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\n\u201cThe data we\u2019re sharing at the Inflammasome Therapeutics summit showcases our ability to stimulate and hyperactivate DCs through inflammasome activity, to drive robust and long-lasting T cell memory,\u201d said Steven M. Altschuler, MD, CEO and Board Chair of Corner. \u201cWhile many approaches focus on suppressing the inflammasome, Corner\u2019s technology represents a true paradigm shift in immunotherapy.\u201d\n<\/p>\n

\nAbout Corner Therapeutics, Inc.
\n
<\/b>Corner Therapeutics is a privately held biotech company developing a new class of multi-purpose dendritic cell-targeting immunotherapies that induce robust memory T cell responses. Corner Therapeutics is exploiting a new scientific paradigm to boost the intelligence of the natural immune response through dendritic cell hyperactivation. Our unique approach engages dendritic cell inflammasomes to induce exceptional memory T cell responses critical for lifelong immunity. Our platform is antigen-agnostic and aims to address an exceptionally wide range of difficult-to-treat cancers and infectious diseases. Corner’s therapy will usher in a new era of rapid, patient-friendly and low-cost treatments able to induce complete and durable protective immunity. Our foundational science originated from the Kagan and Karp labs at the Harvard Medical School and is being advanced by pioneers of immunotherapy. For more information, please visit https:\/\/cornertx.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia:<\/b>
Michael Falcone
\n
MacDougall Advisors
\n
MFalcone@macdougall.bio<\/a>
781-591-3448\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

WATERTOWN, Mass.–(BUSINESS WIRE)–Corner Therapeutics, a biotechnology company exploiting a new scientific paradigm to boost the intelligence of the natural immune response to disease, today announced three presentations of data on its dendritic cell hyperactivation (hDC) platform at the 4th Inflammasome Therapeutics Summit, taking place November 29 to December 1, 2022 in Boston, Massachusetts. Corner has … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-51386","6":"format-standard","7":"category-industry"},"yoast_head":"\nCorner Therapeutics to Present Pre-Clinical Data on their Novel Dendritic Cell Hyperactivation Platform at the 4th Inflammasome Therapeutics Summit - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/corner-therapeutics-to-present-pre-clinical-data-on-their-novel-dendritic-cell-hyperactivation-platform-at-the-4th-inflammasome-therapeutics-summit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Corner Therapeutics to Present Pre-Clinical Data on their Novel Dendritic Cell Hyperactivation Platform at the 4th Inflammasome Therapeutics Summit - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"WATERTOWN, Mass.–(BUSINESS WIRE)–Corner Therapeutics, a biotechnology company exploiting a new scientific paradigm to boost the intelligence of the natural immune response to disease, today announced three presentations of data on its dendritic cell hyperactivation (hDC) platform at the 4th Inflammasome Therapeutics Summit, taking place November 29 to December 1, 2022 in Boston, Massachusetts. Corner has ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/corner-therapeutics-to-present-pre-clinical-data-on-their-novel-dendritic-cell-hyperactivation-platform-at-the-4th-inflammasome-therapeutics-summit\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-30T12:02:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221130005077\/en\/1648968\/21\/CORNER-Logo-Vertical-RGB.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/corner-therapeutics-to-present-pre-clinical-data-on-their-novel-dendritic-cell-hyperactivation-platform-at-the-4th-inflammasome-therapeutics-summit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/corner-therapeutics-to-present-pre-clinical-data-on-their-novel-dendritic-cell-hyperactivation-platform-at-the-4th-inflammasome-therapeutics-summit\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Corner Therapeutics to Present Pre-Clinical Data on their Novel Dendritic Cell Hyperactivation Platform at the 4th Inflammasome Therapeutics Summit\",\"datePublished\":\"2022-11-30T12:02:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/corner-therapeutics-to-present-pre-clinical-data-on-their-novel-dendritic-cell-hyperactivation-platform-at-the-4th-inflammasome-therapeutics-summit\\\/\"},\"wordCount\":539,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/corner-therapeutics-to-present-pre-clinical-data-on-their-novel-dendritic-cell-hyperactivation-platform-at-the-4th-inflammasome-therapeutics-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221130005077\\\/en\\\/1648968\\\/21\\\/CORNER-Logo-Vertical-RGB.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/corner-therapeutics-to-present-pre-clinical-data-on-their-novel-dendritic-cell-hyperactivation-platform-at-the-4th-inflammasome-therapeutics-summit\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/corner-therapeutics-to-present-pre-clinical-data-on-their-novel-dendritic-cell-hyperactivation-platform-at-the-4th-inflammasome-therapeutics-summit\\\/\",\"name\":\"Corner Therapeutics to Present Pre-Clinical Data on their Novel Dendritic Cell Hyperactivation Platform at the 4th Inflammasome Therapeutics Summit - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/corner-therapeutics-to-present-pre-clinical-data-on-their-novel-dendritic-cell-hyperactivation-platform-at-the-4th-inflammasome-therapeutics-summit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/corner-therapeutics-to-present-pre-clinical-data-on-their-novel-dendritic-cell-hyperactivation-platform-at-the-4th-inflammasome-therapeutics-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221130005077\\\/en\\\/1648968\\\/21\\\/CORNER-Logo-Vertical-RGB.jpg\",\"datePublished\":\"2022-11-30T12:02:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/corner-therapeutics-to-present-pre-clinical-data-on-their-novel-dendritic-cell-hyperactivation-platform-at-the-4th-inflammasome-therapeutics-summit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/corner-therapeutics-to-present-pre-clinical-data-on-their-novel-dendritic-cell-hyperactivation-platform-at-the-4th-inflammasome-therapeutics-summit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/corner-therapeutics-to-present-pre-clinical-data-on-their-novel-dendritic-cell-hyperactivation-platform-at-the-4th-inflammasome-therapeutics-summit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221130005077\\\/en\\\/1648968\\\/21\\\/CORNER-Logo-Vertical-RGB.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221130005077\\\/en\\\/1648968\\\/21\\\/CORNER-Logo-Vertical-RGB.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/corner-therapeutics-to-present-pre-clinical-data-on-their-novel-dendritic-cell-hyperactivation-platform-at-the-4th-inflammasome-therapeutics-summit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Corner Therapeutics to Present Pre-Clinical Data on their Novel Dendritic Cell Hyperactivation Platform at the 4th Inflammasome Therapeutics Summit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Corner Therapeutics to Present Pre-Clinical Data on their Novel Dendritic Cell Hyperactivation Platform at the 4th Inflammasome Therapeutics Summit - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/corner-therapeutics-to-present-pre-clinical-data-on-their-novel-dendritic-cell-hyperactivation-platform-at-the-4th-inflammasome-therapeutics-summit\/","og_locale":"en_US","og_type":"article","og_title":"Corner Therapeutics to Present Pre-Clinical Data on their Novel Dendritic Cell Hyperactivation Platform at the 4th Inflammasome Therapeutics Summit - Pharma Trend","og_description":"WATERTOWN, Mass.–(BUSINESS WIRE)–Corner Therapeutics, a biotechnology company exploiting a new scientific paradigm to boost the intelligence of the natural immune response to disease, today announced three presentations of data on its dendritic cell hyperactivation (hDC) platform at the 4th Inflammasome Therapeutics Summit, taking place November 29 to December 1, 2022 in Boston, Massachusetts. Corner has ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/corner-therapeutics-to-present-pre-clinical-data-on-their-novel-dendritic-cell-hyperactivation-platform-at-the-4th-inflammasome-therapeutics-summit\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-30T12:02:13+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221130005077\/en\/1648968\/21\/CORNER-Logo-Vertical-RGB.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/corner-therapeutics-to-present-pre-clinical-data-on-their-novel-dendritic-cell-hyperactivation-platform-at-the-4th-inflammasome-therapeutics-summit\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/corner-therapeutics-to-present-pre-clinical-data-on-their-novel-dendritic-cell-hyperactivation-platform-at-the-4th-inflammasome-therapeutics-summit\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Corner Therapeutics to Present Pre-Clinical Data on their Novel Dendritic Cell Hyperactivation Platform at the 4th Inflammasome Therapeutics Summit","datePublished":"2022-11-30T12:02:13+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/corner-therapeutics-to-present-pre-clinical-data-on-their-novel-dendritic-cell-hyperactivation-platform-at-the-4th-inflammasome-therapeutics-summit\/"},"wordCount":539,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/corner-therapeutics-to-present-pre-clinical-data-on-their-novel-dendritic-cell-hyperactivation-platform-at-the-4th-inflammasome-therapeutics-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221130005077\/en\/1648968\/21\/CORNER-Logo-Vertical-RGB.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/corner-therapeutics-to-present-pre-clinical-data-on-their-novel-dendritic-cell-hyperactivation-platform-at-the-4th-inflammasome-therapeutics-summit\/","url":"https:\/\/pharma-trend.com\/en\/corner-therapeutics-to-present-pre-clinical-data-on-their-novel-dendritic-cell-hyperactivation-platform-at-the-4th-inflammasome-therapeutics-summit\/","name":"Corner Therapeutics to Present Pre-Clinical Data on their Novel Dendritic Cell Hyperactivation Platform at the 4th Inflammasome Therapeutics Summit - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/corner-therapeutics-to-present-pre-clinical-data-on-their-novel-dendritic-cell-hyperactivation-platform-at-the-4th-inflammasome-therapeutics-summit\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/corner-therapeutics-to-present-pre-clinical-data-on-their-novel-dendritic-cell-hyperactivation-platform-at-the-4th-inflammasome-therapeutics-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221130005077\/en\/1648968\/21\/CORNER-Logo-Vertical-RGB.jpg","datePublished":"2022-11-30T12:02:13+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/corner-therapeutics-to-present-pre-clinical-data-on-their-novel-dendritic-cell-hyperactivation-platform-at-the-4th-inflammasome-therapeutics-summit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/corner-therapeutics-to-present-pre-clinical-data-on-their-novel-dendritic-cell-hyperactivation-platform-at-the-4th-inflammasome-therapeutics-summit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/corner-therapeutics-to-present-pre-clinical-data-on-their-novel-dendritic-cell-hyperactivation-platform-at-the-4th-inflammasome-therapeutics-summit\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221130005077\/en\/1648968\/21\/CORNER-Logo-Vertical-RGB.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221130005077\/en\/1648968\/21\/CORNER-Logo-Vertical-RGB.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/corner-therapeutics-to-present-pre-clinical-data-on-their-novel-dendritic-cell-hyperactivation-platform-at-the-4th-inflammasome-therapeutics-summit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Corner Therapeutics to Present Pre-Clinical Data on their Novel Dendritic Cell Hyperactivation Platform at the 4th Inflammasome Therapeutics Summit"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51386","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=51386"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51386\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=51386"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=51386"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=51386"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}